Biochemical Pharmacology 1991: Vol 42 Index

38 Pages·1991·13.8 MB·English

(FOUNDED BY SIR RUDOLPH A. PETERS)
SUBJECT INDEX FOR VOLUME 42, 1991
PREPARED BY W. COCKS
Oxford : New York
Seoul : Tokyo
BIOCHEMICAL PHARMACOLOGY
EDITORIAL BOARD
Chairman: A. D. WELCH
Regional Editors
European Continent
Prof. PETER ALEXANDER Biochemical Pharmacology U.K. Office, P.O. Box 11,
(Executive Editor) Cullompton, Devon EX15 1TQ, U.K.
Prof. J. GIELEN Université de Liége, Laboratoire de Chimie Médicale, Insti-
tut de Pathologie, B-4000 Sart-Tilman par Liége 1, Belgium
Associate Editors
Prof. MARTIN K. CHURCH _ Clinical Pharmacology, Centre Block, Southampton General
Hospital, Southampton SO9 4XY, U.K.
Dr. PIERRE LADURON Département de Biologie, Rhéne-Poulenc Santé, Centre de
Recherches de Vitry, 13, quai Jules Guesde, 94403 Vitry sur
Seine, France
American Continent
Prof. ALAN C. SARTORELLI Yale University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Associate Editors
Prof. YUNG-CHI CHENG Yale University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Prof. PRISCILLA S. DANNIES Yale University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Prof. R. H. RoTH Yale University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Dr. B. Z. RENKIN Yale University School of Medicine, Department of
Pharmacology, 47 College Street, Suite 227, New Haven,
Connecticut 06510-3209, U.S.A.
Commentaries Editor
Prof. C. NORMAN GILLIS Yale University School of Medicine, Departments of Anes-
thesiology and Pharmacology, Sterling Hall of Medicine, 333
Cedar Street, P.O. Box 3333, New Haven, Connecticut
06510-8066, U.S.A.
Publishing and Advertising Offices: Headington Hill Hall, Oxford OX3 OBW (Oxford
794141), and 395 Saw Mill River Road, Elmsford, NY 10523. Published two issues per
month. Annual Institutional Subscription Rate (1992) £1410.00 (US$2560.00). Two-year
Institutional Rate (1992/93) £2679.00 (US$4864.00). Sterling prices are definitive. US
dollar prices are quoted for convenience only, and are subject to exchange rate fluctuation.
Prices include postage and insurance and are subject to change without notice. Subscrip-
tion rates for Japan are available on request. Personal subscription rate for those whose
library subscribes at the regular rate is available on request. Subscription enquiries from
customers in North America should be sent to: Pergamon Press Inc., 395 Saw Mill River
Road, Elmsford, NY 10523, U.S.A., and from the remainder of the world to: Pergamon
Press plc, Headington Hill Hall, Oxford OX3 OBW, U.K.
Whilst every effort is made by the publishers and editorial board to see that no inaccurate or gwSieiE Y
misleading data, opinion or statement appears in this journal, they wish to make it clear that the
data and opinions appearing in the articles and advertisements herein are the sole responsibility of
the contributor or advertiser concerned. Accordingly, the publishers, the editorial board and editors
and their respective employees, officers and agents accept no responsibility or liability whatsoever
for the consequences of any such inaccurate or misleading data, opinion or statement.
Application to mail at second class postage rate is pending at RAHWAY, NJ. Postmaster send
address corrections to Biochemical Pharmacology, c/o Pergamon Press Inc., 395 Saw Mill River
Road, Elmsford, NY 10523, U.S.A.
Copyright © 1992 Pergamon Press plc
EDITORIAL ADVISORY BOARD
American Continent
JuLius AXELROoD—National Institutes of Health, Bethesda, YUTAKA KosBayAsHiI—Ko-By Associates, 60 Audubon Road,
Wellesley, MA
MICHAEL R. BoyD—NCI-FCRDC, Frederick, MD WALTER M. LovENBERG—Marion Merrell Dow Research In-
EDWARD BrESNICK—Department of Pharmacology and Toxi- stitute, Cincinnati, OH
cology, Dartmouth Medical School, Hanover, NH P. N. MAGeE—Temple University School of Medicine,
D. N. BRINDLEY—Faculty of Medicine, University of Alberta, Philadelphia, PA
Edmonton, Canada G. J. MANNERING—Department of Pharmacology, University
MICHAEL J. BROWNSTEIN—National Institutes of Health, of Minnesota Medical School, Minneapolis, MN
Bethesda, MD | TaG E. MANsouR—Department of Pharmacology, Stanford
JACK R. Cooper—Yale University School of Medicine, New University Medical Center, Stanford, CA
Haven, CT PauL_ B. McCay—Oklahoma Medical Research Foundation,
JAMES K. Cowarp—College of Pharmacy, University of Oklahoma City, OK
Michigan, Ann Arbor, MI HERBERT Y. MELTZER—Case Western Reserve University,
IAN CrEESE—Center for Molecular and Behavioral Neuro- Cleveland, OH
science, Aidekman Research Center, Newark, NJ EsTEBAN Mezey—Johns Hopkins University School of
JOHN W. DALy—National Institutes of Health, Bethesda, MD Medicine, Baltimore, MD
Erwin G. Erpés—Department of Pharmacology, University DANIEL W. NEBERT—Department of Environmental Health,
of Illinois, College of Medicine, Chicago, IL University of Cincinnati, Cincinnati, OH
MariA ERECINSKA—University of Pennsylvania, Philadelphia, CHARLES A. NicHo_—Cannam Enterprises, 1508 Ward Street,
PA Durham, NC
Ray W. FuLLer—Lilly Research Laboratories, Indianapolis, RosertT E. Parks, JR—Brown University, Providence, RI
IN GABRIEL L. PLAA—University of Montreal, Quebec, Canada
RosBert C. GALLO—National Institutes of Health, Bethesda, EuGENE Roserts—City of Hope Medica! Center, Duarte,
MD CA
JAMES R. GILLETTE—National Institutes of Health, Bethesda, JEROME A. RotH—State University of New York, Medical
Center, Buffalo, NY
RoBert I. GLAZER—Georgetown University, Washington, CHARLES O. RUTLEDGE—School of Pharmacy, Purdue Univer-
DC sity, West Lafayette, IN
I. Davip GOLDMAN—Medical College of Virginia, Richmond, Boris TABAKOFF—National Institutes of Health, Bethesda,
THEODORE E. GRAM—1036 Welsh Drive, Rockville, MD JOHN F. TALLMAN—Neurogeu, 35 Northeast Industrial Road,
M. R. HANLEY—School of Medicine, University of California, Branford, CT
Davis, CA SNoRRI Sv. THORGEIRSSON—National Institutes of Health,
G. H. Hitcuincs—Wellcome Research Laboratories, Research Bethesda, MD
Triangle Park, NC Davip C. U’PRICHARD—ICI Americas Inc., Stuart Pharma-
Louis J. IGNARRO—UCLA School of Medicine, Department ceuticals, Wilmington, DE
of Pharmacology, Los Angeles, CA MARTHA VAUGHAN—National Institutes of Health, Bethesda,
WILLIAM B. JAKoBy—National Institutes of Health, Bethesda, MD
MD NorMAN WEINER—Abbott Laboratories, Abbott Park, IL
Davip G. JoHNs—National Institutes of Health, Bethesda, ARNOLD D. WELCH (Chairman)—Frederick Cancer Research
MD Facility of National Cancer Institute, Frederick, MD
HAROLD KALANT— University of Toronto, School of Medicine, JOHN R. WILLIAMSON—University of Pennsylvania, Philadelphia,
Toronto, Ontario, Canada PA
European Continent
F. M. BELPAIRE—J. F. and C. Heymans Institute of Pharma- G. MILLIGAN—Department of Biochemistry, University of
cology, Rijksuniversity, Ghent, Belgium Glasgow, Glasgow, U.is.
A. G. H. BLAKELEY—Department of Physiology, The Univer- P. Mo_peus—Department of Toxicology, Karolinska Insti-
sity, Leicester, U.K. tute, 104 01 Stockholm 60, Sweden
K. W. Bock—Institute of Toxicology, Tiibingen University, G. J. MuLpER—Department of Toxicology, University of
F.R.G. Leiden, Sylvius Laboratories, P.O. Box 9503, 2300 RA
J. CALDWELL—St. Mary’s Hospital Medical School, London, Leiden, The Netherlands
K. J. NETTER—Department of Pharmacology and Toxicology,
R.A. J. CHALLIss—Department of Pharmacology, University Philipps University, Marburg, Germany
of Leicester, Leicester, U.K.
H. Nout—Institute of Pharmacology and Toxicology, Uni-
T. A. CoOnNNoRS—MRC Toxicology Unit, Carshalton, Surrey,
versity of Vienna, Vienna, Austria
U.K
A. J. Paine—St Bartholomew’s Hospital Medical School,
E. De CLERCQ—Rega Institute for Medical Research, Univer-
London, U.K.
sity of Leuven, Belgium
B. K. PAakK—Department of Pharmacology and Therapeutics,
J. FrereE—Institute de Chimie, Université de Liége, Liége,
University of Liverpool, Liverpool, U.K.
Belgium
E. Reip>—Guildford Academic Associates, Guildford, Surrey,
T. GODFRAIND—Université Catholique de Louvain, Belgium
R. J. GRYGLEwski—School of Medicine, Cracow, Poland U.K
J. HAMON—INSERM U288, Neurobiol Cellulaire et Fonc- E. REINER—Yugoslav Academy of Sciences and Arts, 4100
tionnelle, Faculté de Medecine Pitie-Salpetriere, 91 Blvd de Zagreb, Yugoslavia
l'H6pital, F-75634 Paris Cedex 14, France A. G. Renwick—University of Southampton, Faculty of
J. HANOUNE—INSERM U99, H6pital Henri Mondor, Creteil, Medicine, Southampton, U.K.
France P. J. RopeErts—Department of Physiology and Pharmacology,
J. A. HickKMAN—Department of Physiological Sciences, Medical and Biological Sciences Building, Southampton,
University of Manchester, Manchester, U.K. U.K.
I. JankU—Institute of Pharmacology, Czechoslovak Academy M. SANDLER—Bernhard Baron Memorial Research Labora-
of Sciences, Czechoslovakia tories, Queen Charlotte’s Maternity Hospital, London, U.K.
P. JENNER—Department of Pharmacology, King’s College, H. Sies—Institut fiir Physiologische Chemie 1, Universitat
London SWS 8AF, U.K.
Diisseldorf, Diisseldorf, Germany
H. Kappus—Freie Universitat Berlin, Germany
J. Skopa—Institute of Organic Chemistry and Biochemistry,
J. LuUNpDBERG—Department of Pharmacology, Karolinska
Czechoslovak Academy of Sciences, Prague, Czechoslo-
Institutet, Stockholm, Sweden
vakia
G. P. MANNAERTS—Dienst Farmakoligie, Campus Gasthuis-
B. Testa—Department of Pharmacy, University of Lausanne,
berg, Onderwijs en Navorsing, Herestraat, 3000 Leuven,
Lausanne, Switzerland
Belgium
K. Tipton—Department of Biochemistry, University of
D. Mansuy—Universiteé René Descartes, Laboratoire de
Dublin, Trinity College, Ireland
Chimie et de Biochemie, Pharmacologiques et Toxicolo-
giques, 45 rue des Saints-Péres, 75270 Paris Cedex 05, V. UL_rich—Fakultat fiir Biologie, Universitat Konstanz,
France Konstanz, Germany
A. E. M. McLean—Department of Clinical Pharmacology, P. WALDMEIER—Ciba-Geigy Limited, CH-4002 Basle, Switzer-
University College Hospital Medical School, London, land
U.K M. B. H. YoupiMm—Technion-Israel Institute of Technology,
Cha MeApE—Department of Pharmacology, Boehringer Faculty of Medicine, Department of Pharmacology, Bat
Ingelheim KG, D-6507 Ingelheim am Rhein, F.R.G. Galim, Haifa, Israel
Asia and Pacific Rim
K. KurryAMA—Kyoto Prefectural University of Medicine, T. WataBE—Tokyo College of Pharmacy, Tokyo, Japan
Kyoto, Japan
AIMS AND SCOPE
BIOCHEMICAL PHARMACOLOGY is an international journal which publishes research findings in pharmacology
deriving from investigations that employ the disciplines of biochemistry, biophysics, molecular biology, genetics,
structural biology, computer models and/or physiology. Reports of studies with intact animals, organs, cells,
subcellular components, enzymes or other cellular molecules and model systems are acceptable if they define
mechanisms of drug action. Descriptive mathematical models including those involving computer techniques are
also welcome. Experiments involving the use of drugs to elucidate physiological and behavioral mechanisms in
living organisms are also within the scope of the journal. In general, papers which record concentrations of drugs
and metabolites in body fluids will only be accepted if they contribute to an understanding of biochemical and
biophysical mechanisms. The Editors, however, reserve the right to publish any papers of major interest in the
field. Only contributions in English can be considered or published.
The journal publishes the following types of communication:
(1) Full-length Papers. These consist of a body of work presenting original findings relating to the question
proposed by the investigators undertaking the research.
(2) Short Communications. These consist of an original body of work of narrower scope but of the same quality
as the above. By definition, these papers are shorter than full-length manuscripts.
(3) Rapid Communications. These promote rapid dissemination of timely and significant observations within
the scope of the journal. Manuscripts must be submitted in English and will be judged as appropriate for
publication as rapid communications on the basis of their immediate importance. They should be written to
emphasize clearly the novel aspects of the research. These criteria will be applied strictly. In order to speed up
the publication of rapid communications, authors are encouraged to use the special laysheets available from any
of the Regional Editors.
(4) Commentaries are short commissioned review articles (3000-5000 words in length). They are designed to
be editorial statements on selected topics, and should not be exhaustive reviews. Primarily, Commentaries are
intended to stimulate thought. They can be controversial, and can either focus on areas subject to much activity,
or draw attention to relatively neglected fields in which there are both the opportunity and the need for research
in biochemical pharmacology. Particularly welcome will be Commentaries in which authors present their personal
view on the state of the subject on which they are reporting, and give their view as to where in the near or distant
future the subject may be moving. Authors are especially encouraged to take issue with popular dogmas. The
Commentary series is edited by Professor C. Norman Gillis.
In order to increase the exchange of information and ideas, the Journal will also publish Comments on a
Commentary, in which selected, highly qualified authorities are invited to offer their own observations on
Commentary articles, which will be published in the same issue of the Journal, and thus provide some alternative
thoughts on important areas of research. For further information see Biochem Pharmacol 31, 2568 (1982).
While the final decision on selection of authors for either Commentaries or Comments on a Commentary will
be made at the discretion of the editor, suggestions from readers will be welcome. These should be addressed
to: Professor C. N. Gillis, Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street,
New Haven, Connecticut 06510.
(5) Meeting Reports. The journal is prepared to publish as preliminary communications short, factual two-page
summaries of selected papers from small meetings or conferences. The meetings should be those where attendance
is by invitation and all papers to be published will be refereed. Organizers who wish to have their meetings
published in this way should contact the appropriate Regional Editor.
Notes for Contributors can be found in all issues and Abbreviations in issues 1 and 7
BIOCHEMICAL PHARMACOLOGY
SUBJECT INDEX FOR VOLUME 42, 1991
A1110U
inhibition of herpes and human ribo- 2-Acetylpyridine 5-((2-chloroanilino)-
nucleotide reductases 91 thiocarbonyl )-thiocarbono-
A80915A hydrazone
inhibition of gastric H*t,Kt-ATPase inhibition of herpes and human ribo-
2019 nucleotide reductases 91
Acetaldehyde N-Acetyltransferase
oxidation by aldehyde dehydrogenase in liver
from human erythrocytes 979 effect of chloroquine and prima-
Acetaminophen quine 954
effect on AZT metabolism in effect of streptolysin 0 702
hepatocytes 1475 phenotype and genotype in humans
cytotoxicity of regioisomers in 1007
hepatocyte cultures 1137 «)-Acid glycoprotein — dicoumarol
metabolism in rat in vivo, effect of effect of tricyclic drugs on CD
chronic hypoxia 1029 spectra 729
protein binding S197 Aciduria
sulphation by isolated liver cells etomoxir induced 1637
45 Acridine carboxamide
Acetiamine 9-acridone formation in liver
iodine complex and antithyroid cytosol 1879
activity S89 Actin-binding protein
Acetone effect of toluene 805
induction of cytochrome P450 iso- Acyclic nucleoside phosphonates
enzymes in liver S143 antiviral activity 963
N-Acetyl-p-benzoquinoneimine Acyclovir
pr asais *etudes $197 permeation of human erythrocytes 147
Acetylcholine Acy1-CoA synthetase
acidification of adrenal gland in liver, effect of perfluoro-
perfusate S216 decanoic acid 295
evoked catecholamine release from Acyl glucuronides
adrenals 973 reactivity 2289, 2301
Acetylcholinesterase 1-Acylglycerophosphocholine acetyl-
platelet plasma membrane, effect of transferase
cholesterol supplementation 2037 in kidney, induction by perfluoro-
in red cells, physostigmine-inhibited, octanoic acid 1921
decarbamoylation 515 Adenosine
release from adrenal gland S216 effect on atrial 86Rb efflux 655
second site of action of soman 2040 inhibition of phosphorylation of
soman and sarin inhibition of troponin I in heart 685
molecular forms, reactivation by Adenosine analogues
HI-6 329 effect on ATP in erythrocytes 1767
N-Acetylcysteine Adenosine Al receptor
metabolism by human endothelial in brain, effect of halothane on
cells 13 interaction witn G protein 1313
effect on nitric oxide generation Adenosine-3' ,5'-monophosphate
from nitroglycerin 1433 in adipose tissue, effect of phorbol-
protection against pulmonary edema 12-myristate l3-acetate 1/791
S47 in astrocytes, a&- and B-adrenoceptor
scavenging of hypochlorous acid 2244 regulation 59
N-Acetyl-L-glutamate in CHO cells, isoproterenol induced
in hepatocytes, effect of sodium accumulation 1683
benzoate 645 in chromaffin cells, effect of
2-Acetylpyridine 5((2-chloroanilino)- clonidine 2011
thiocarbonyl )-thiocarbonohydraz- in eosinophils, effect of phospho-
2 BIOCHEMICAL PHARMACOLOGY
Adenosine-3',5'-monophosphate(contd. ) Adrenal gland(contd. )
phosphodiesterase inhibitors 937 depolarization induced acidification
formation in cloned muscarinic of perfusates S216
receptors 1645 electrically-evoked catecholamine
in HL-60 cells, elevation by trans- release 973
methylation inhibitors 1/761 effect of idebenone on catecholamine
in neutrophils, ionophore A2318/7- formation 95]
induced elevation ‘$105 imidazole receptors and signal
in P388 cells, effect of cis-diammine transduction in chromaffin cells
dichloroplatinum(II) 285 2011
in parotid gland, effect of epidermal Adrenaline
growth factor 2333 binding to B-adrenergic receptors in
in platelets, endothelial cell- S49 cells 1069
dependent regulation 253 dependent increase in hepatocyte
in S49 lymphoma cells, effect of calcium, effect of menadione 1977
bromoacetylated derivatives of effect on verapamil binding in
alprenolol and pindolol S212 hepatocytes 2239
in tracheal smooth muscle, effect of a-Adrenoceptor
AH 21-132 663 in astrocytes, regulation of
VIP-stimulated response in pinealo- cyclic AMP accumulation 59
cytes, effect of ethanol 1601 in <a role in ethanol toxicity
Adenosine(5')tetraphospho(5' ) adenosine
in P388 cells, effect of cis-diammine «]l=Adrenoceptors
dichloroplatinum(II) 285 liver, effect of menadione 1977
(H+,Kt)-Adenosine triphosphatase pinealocytes, effect of ethanol on
gastric VIP-stimulated cyclic AMP and
inhibition by A80915A 2019 cyclic GMP responses 1601
inhibition by SK&F 96067 123 a2-Adrenoceptors
inhibition by sofalcone 1447 platelets, p-aminoclonidine
effect of lansoprazole enantiomers binding ~569
1875 p-Adrenoceptors
(Na+,Xt)-Adenosine triphosphatase astrocytes, regulation of cyclic AMP
in heart, inhibition by LND 623 S223 accumulation 59
Adenosine triphosphate brain, effect of antidepressants
binding to LLC-PK} cells 1495 1525
in erythrocytes, effect of adenosine S49 cells, adrenaline binding 1069
analogues 1/767 P1-Adrenoceptors
in kidney microsomes, effect of CHO-Hu cells, effect of nebivolol
cyclosporine A 71 1683
in leukemic cells, effects of mafos- in skeletal muscle 1783
famide and etoposide 1859 2-Adrenoceptors
role in insulin release from pancreat- CHO-Hu cells, effect of nebivolol
ic islets 595 1683
role in sinusoidal transport of lymphocytes and lymphoma cells 1329
dibromosulfophthalein 1997 skeletal muscle 1/783
Adenosine triphosphate analogues Adriamycin
effect on ribonucleotide reductase polyploidy induction 2199
759 resistance in vivo 391
S-Adenosylhomocysteine toxicity and DNA damage 2253
effect on ATP in erythrocytes 1/767 toxicity in heart mitochondria,
Adenylate cyclase effect of schisanhenol 1805
in adipose tissue, effect of phorbol AF-DX 116
12-myristate 13-acetate 1/791 affinity at cloned mescarinic
in alveolar macrophages, effect of receptors 1645
sensitization 485 effect on muscarinic receptors in
dopamine sensitive in brain, effect diabetic rat prostate $113
of piflutixol 229 Aging
in lymphoma cells 1069, 1329 effect on glutathione S-transferase
effect of p- bromophenacy] bromide subunits in rat liver 491
1941 Aglycone flavonoids
in parotid gland, epidermal growth effect on eicosanoid synthesis and
factor-mediated stimulation 2333 lipid peroxidation 1673
Adipocytes Agmantine
effect of polymyxin B on glucose ornithine decarboxylase regulation
transport 1399 1045 aG2Phoea oLoae A
Adipose tissue AR 21-132
effect of phorbol 12-- myristate inhibition of cyclic AMP phospho-
13-acetate on cyclic AUP in 1791 diesterase in tracheal smooth
Adrenal gland muscle 663
effect of brovincamine on catechol- Ah receptor
amine secretion 190 in Mz-Hep-1 cells 521i
carbonyl reduction in subcellular Airway smooth muscle
fractions, rodents S189 cyclic AMP phosphodiesterase
BIOCHEMICAL PHARMACOLOGY
Airway smooth muscle(contd.) ¥y¥-Aminobutyric acid B receptor
inhibition by AH 21-132 663 in brain, effect of antidepressants
AL-1576 1525
effect on ascorbate oxidation 1273 p-Aminoclonidine
Albumin ~ binding to platelets 569
in CSF, indomethacin binding 799 N- (6-Aminohexy1 )-5-chloro-1-naphthal-
human serum enesulfonamide
diflunisal acyl glucuronide effect on cyclic AMP in neutrophils
interaction 2301 S105
PGE} binding in allergic subjects stimulation of K* transport in human
609 epithelia 1039
Aldehyde dehydrogenase 5-Aminolevulinic acid
in cyclophosphamide-resistant effect on mixed-function oxidase and
L1210 cells 1933 UDP-glucuronosyltransferase in
in erythrocytes, kinetics 979 Hep G2 cells’ 1307
in liver 5-Aminolevulinic acid synthase mRNA
effect of disulfiram and metabol- in embryo hepatocytes, effect of
ites 1361 dihydropyridines, dihydroquinol-
retinaldehyde oxidation 1279 ines, sydnones and N-ethylproto-
Aldose reductase porphyrin IX 475
in lens, inhibition by (2,6-dimethyl- Aminopeptidase P
phenylsulphonyl )nitromethane ¥$ y Be in oO kinin analogue metabolism
Aldose reductase inhibitors 21
inhibition of ascorbate oxidation Aminopterin
1273 5,8-dideaza analogues, metabolism by
Alimemazine liver folylpolyglutamate
iodine complex and antithyroid synthatase 833
activity S89 4-Aminopyridine
Alizarin yellow R effect on agonist induced atrial
antioxidative activity 1177 86Rb efflux 655
Allergy Aminopyrine
PGE; binding to serum proteins 609 uptake by gastric glands, effect of
Allosteric muscarinic antagonists 199 E3810 and omeprazole 321
Alloxan Aminopyrine N-demethylase
thiol reactivity, hydrophilicity in liver microsomes, effect of
and stability 1385 streptolysin O 702
Alprazolam 5-Aminosalicyclic acid
attenuation of discontinuation effects neutrophil derived metabolite 1869
by carbamazepine S99 2-Aminothiazole
Alprenolol iodine complex and antithyroid
bromoacetylated derivatives, partial activity S89
agonistic activity $212 3-Amino-1,2,4-triazole
Althesin effect on brain catalase 699
effect on erythrocyte membrane Amiodarone
fluidity 1947 accumulation by alveolar macro-
Alveolar macrophages phages S151
accumulation of amiodarone and Amphotericin B
desethylamiodarone S151 effect on erythrocyte membrane
adenylyl cyclase responsiveness 485 fluidity 1947
Amiloride Ampicillin
effect on glucose 6-phosphatase in effect on neutrophil cytolysis 2317
hepatocytes S27 Amsacrine
effect on hepatic bile acid uptake polyploidy induction 2199
$135 Anaesthetics, general
Amine oxidases 2,6-diisopropylphenol effects on
dopamine metabolism in retina 2355 oxidative phosphorylation in
semicarbazide-sensitive in breast liver 8/7
cancer induced with 7,12-dimethyl- effect on erythrocyte membrane
benz(~)anthracene 263 fluidity 1947
Aminoacridines Anaesthetics, local
toxicity and DNA damage 2253 interaction with neuronal 1,4-
4-Aminobutyraldehyde dihydropyridine binding sites
GABA gormation in synaptosomes, 213
effect of gabaculine 447 Androstenedione 6B-hydroxylase
¥-Aminobutyric acid in liver, effect of anhydroerythro-
formed from 4-aminobutyraldehyde in mycin 2085
synaptosomes 44/7 Androstenedione 16-hydroxylase
X¥-Aminobutyric acid A receptor in liver, effect of vitamin E 2107
effect of carbamazepine after Angiotensin I
alprazolam discontinuation S99 metabolizing enzymes in mesenteric
modulation of morphine inhibition arterial bed perfusate 1897
of noradrenaline release S121 Angiotensin II
X¥-Aminobutyric acid B receptor pulmonary vasoconstriction, effect
4 BIOCHEMICAL PHARMACOLOGY
Angiotensin II(contd.) Arabinosyl-5-azacytosine
of diphenyleneiodinium R9 5-fluorouracil interaction in colon
regulation of phosphate transport in cancer cells 409
cardiac myocytes 1123 Arachidonic acid
role in ovulation 715 metabolism in blood cells, effect of
Angiotensin converting enzyme SK&F 105561 and 105809 813
in serum, inhibition by enalaprilat metabolism in platelets, effect of
1729 fish oil hydroxyfatty acids 959
Anhydroerythromycin release in astrocyte cultures, effect
inhibition of drug oxidation 2085 of pertussis and cholera toxins
Aniline hydroxylase 1267
in hepatocyte cultures 381 Arecoline
in liver microsomes effect on Ca2+ release from gastric
effect of exercise 181 parietal cells 839
effect of streptolysin O 702 Arginine
Antagonist drugs dependent histamine H}-receptor-
binding promiscuity Sl mediated cyclic GMP production
Antibiotics in lung 271
DNA base damage 1595 Aroclor 1254
effect on erythrocyte membrane effect on plasma lipoprotein metab-
fluidity 1947 olism in chicks 1493
effect on neutrophil cytolysis 2317 Arsenic
Anticholinesterases glutathione-dependent biliary
effect on protein accessibility in excretion 465
electroplax 1463 Artery
Anticoagulants pulmonary, effect of diphenylene-
dermatan sulfates 1609 iodonium on hypoxic constriction
Antidepressants R9
effect on GABAp and p-adrenoceptors Arthritis
in brain 1525 effect of flosulide and metabolites
Antifolates 1913
effect on keratinocytes S39 Aryl hydrocarbon hydroxylase
Anti-inflammatory drugs in Mz-Hep-1 cells 521
granulocyte function 1913 2-Arylpropionic acids
Antioxidant enzymes chiral inversion Rl, 1905
in liver, effect of cadmium + ethanol Ascorbic acid
S9 in hepatocytes, effect of diquat-
Antioxidants induced redox cycling 883
calcium antagonists and B-blockers effect on peroxidative stress in
735 lymphoid cells 450
B-carbolines 459 Ascorbic acid 2-Q-e-glucoside
methylene blue 499 in vivo formation in guinea pigs
peroxidative stress in lymphoid cells and rats 625
450 Aspartic acid
e&l-Antiproteinase in hepatocytes, effect of sodium
protection by lipoate against benzoate 645
oxidation by hypochlorous acid stimulation of Nat efflux from
2244 forebrain membrane vesicles 1811
Antithrombotic agents Astrocytes
dermatan sulfates 1609 eé- and P-adrenoceptor regulation of
Aorta cyclic AMP accumulation 59
atherosclerosis and fatty acid BCNU inhibits S6 kinase activation
hydroxyderivatives 279 553
induction of stress protein in G-protein controlled prostaglandin
endothelial cells by prosta- synthesis 1267
glandins 777 Atenolol
nitric acid generation from nitro- antioxidant activity 735
prusside S157 Atherosclerosis
phosphodiesterase isoenzymes in 545 13-hydroxylinoleic acid and 15-
sialic acid and calcium channel hydroxyarachidonic acid in aorta
ligands S/77 279
TXA2/PGH2 receptors 537 Atropine
Aprindine affinity at cloned muscarinic
effect on palytoxin-induced catechol- receptors 1645
amine secretion 17 effect on muscarinic receptors in PaaSRaO*n i Y si ni s
9$-D-Arabinofuranosyladenine diabetic rat prostate S113
effect on ATP in erythrocytes 1/767 13-Azapinane TXA2 analogues
1B-D-Arabinofuranosylcytosine TXA2/PGH2 receptor subclasses 537
5-fluorouracil interaction in colon 8-Azidoadenosine
cancer cells 409 effect on formycin B transport by
metabolism and cytotoxicity in macrophages 247 aPeNegPRe e a ts
leukemia cells, effect of 3'-Azido-3'-deoxythymidine
bryostatin 1 853 exposed Hg cells, thymidine and
BIOCHEMICAL PHARMACOLOGY
3'-Azido-3'-deoxythymidine(contd. ) Bile flow
AZT metabolism in 905 effect of colchicine and carbon
glucuronidation by human liver 559 tetrachloride 2323
effect on PC12 cells R5 Bilirubin
effect of probenecid and acetamino- in serum, effect of cyclosporin A
phen on catabolism in hepato- 2053
cytes 1475 Bilirubin dimethylester
toxic effects in male rat 1293 glutathione conjugates 1969
m-Azidopyrimethamine 2',2'-Bipyridyl
effect on keratinocytes S39 plus desferrioxamine, effect on
Plasmodium falciparum 1633
B859-35 2',/7'-Bis(2-carboxyethyk)-5(6)-
cancer therapy 1511 carboxyfluorescein
Bacitracin efflux from intestinal epithelial
DNA base damage 1595 cells S33
Bay K 8644 1,3-Bis(2-chloroethyl )-l-nitrosourea
cardiovascular activity, effect of inhibition of S6 kinase activation
neuraminidase S//7 . by growth factors 553
Bemoradan Bis(p-nitrop)h pheonspyhalte
cardiac phosphodiesterase inhibitor inhibition of carboxylesterases
679 1335
Benfluron N,N'-Bis(2-pyridylmethylene)-1,4-
effect on respiratory processes in butanediammine(N,N',N'N'''''/')F-
tumour cells S214 Cu(I1I)-diperchlorate
Benoxaprofen induced oxidative stress, effect of
cytochrome P450 induction and glutathione 1821
peroxisomal proliferation 109 Bleomycin
Benzaldehyde cytotoxicity on electropermeabilized
role in toluene neurotoxicity 879 cells S67
1,2-Benzanthracene DNA degradation, effect of flavon-
effect on hepatocytes cultured with oids 1673
dimethyl sulphoxide S17 induced lung fibrosis, effect of
Benzene derivatives taurine + niacin 1115
induction of cytochrome P450 iso- Bleomycin hydrolase
enzymes in liver S143 in lung and skin, mouse strain
Benzimidazole E3810 differences 195
inhibition of gastric acid secretion, Bombesin
effect of glutathione 321 mediator of neoplasia 1511
Benzoate Bone marrow
inhibition of gluconeogenesis and effect of AZT 1293
ureagenesis 645 Bradykinin
Benzocaine metabolizing enzymes in mesenteric
action at calcium channels 213 arterial bed perfusate 1897
Benzodiazepines stimulation of competent 3T3 cells
carbamazepine after alprazolam 117
discontinuation S99 Bradykinin analogues
Benzo(a)pyrene metabolism by plasma aminopeptidase
interaction with cytochrome P450c Pee
and NADPH-cytochrome P450 Brain
reductase 97 effect of 3-amino-1,2,4-triazole on
Benzphetamine N-demethylase catalase activity 699
in liver microsomes effect of antidepressants on GABAp
effect of interferonax 311 and B-adrenoceptors 1525
effect of methapyrilene 1093 chick embryo, effect of ethanol 223
(4-Benzyl )-phenoxy-2-morpholinium chicken, altered calmodulin kinase
ethane chloride II after organophosphate treat-
interaction with membrane phospho- ment 171
lipids 2099 ethanol effects on synaptosomal
Beta-blockers calcium, phosphatidylinositol and
free radical scavenging and inhibit- phosphatidylcholine 39
ion of lipid peroxidation 735 fish oil and oxygen toxicity 1353
Bezafibrate flavin-containing monooxygenase in
effect on hepatic microsomal electron 442
transport chains 2057 effect of halothane on adenosine Al
Bile and 5-HTj,q receptors 1313
arsenic excretion 465 histidine decarboxylase in 217
polyethylene glycol excretion 1775 5-HT» receptor regulation 1099
Bile acids effect of 1-methyl-4-phenyl-2,3-
in serum, effect of cyclosporin A dihydropyridinium and l-methyl-4-
2053 phenylpyridinium on mitochondrial
uptake in hepatocytes, effect of function 913
amiloride and 4,4'-diisothiocyano- monoamine oxidase A inhibition by
2,2'-disulfonic stilbene $135 neurocatin 2351
BIOCHEMICAL PHARMACOLOGY
Brain(contd. ) Buthionine sulphoximine(contd. )
morphine effect on monoamine effect on perfluoroisobutene induced
metabolism 1107 pulmonary edema S47
morphine inhibition of noradrenaline Butylated hydroxytoluene
release $121 effect on membrane fluidity 1587
effect of morphine tolerance-depend-
ence and abstinence on k-opiate
receptors 1302 Cadmium
Na* efflux from membrane vesicles hepatotoxicity, effect of ethanol S9
1811 effect on palytoxin-induced catechol-
nitric oxide synthase in 1849 amine secretion 1/7
K-Opiate receptor down-regulation Cadralazine
25 effect on myeloperoxidase 1844
T-2 toxin metabolism 949 Caffeic acid
Breast cancer antioxidative activity 11/77
7,12-dimethylbenz() anthracene Calcium
induced, amine oxidases in 263 binding to dipalmitoyl phosphatidic
Breast cancer cells MCF-7 acid films, effect of cationic
drug resistance in vivo 391 amphiphilic compounds S6l
menadione-induced DNA damage 1961 in CHO cells, effect of l-methyl-2-
effect of triphenylethylene derivat- nitrosoimidazole 2153
ives on progesterone and estrogen effect on dopamine receptor agonist
receptors 1837 binding in pituitary and 73l5a
Breast tumour transplants tumours 2163
5-fluorouracil incorporation into homeostasis in hepatocytes, effect
RNA and inhibition of thymidine of menadione 1977
kinase 2367 influx in chromaffin cells
Bredinin effect of brovincamine 190
effect on ATP in erythrocytes 1/767 effect of imidazole-receptor
Brij 58 binding agents 2011
activation of morphine-UDP-glucur- effect of palytoxin 17
onosyltransferase in liver S55 in LLC-PK} cells, ATP-induced
Bromobenzoylmethyladamantylamine changes 1495
effect on agonist induced atrial in lung, effect of taurine + niacin
Rb efflux 655 on bleomycin-induced increase
Bromodeoxyuridine 1115
incorporation into DNA in colorectal mobilization in chick embryos,
tumour cells 131 effect of ethanol 223
p-Bromophenacyl bromide in multidrug resistant ovarian
~ inhibition of adenylate cyclase 194] cancer cells 1427
N-Bromosuccinimide in neutrophils and monocytes, effect
effect on zacopride binding in of cytochalasin B 425
NG108-15 cells 1453 receptor activated inflow system in
Brovincamine hepatocytes 2239
effect on catecholamine secretion release from gastric parietal cells,
from adrenal medullary cells 190 effect of muscarinic agonists and
Brush border membrane vesicles antagonists 839
partition coefficients 2259 release from kidney mitochondria,
Bryostatin 1 effect of cyclosporin A 2193
effect on ara-C metabolism and role in cytotoxicity of topoisomerase
cytotoxicity 853 inhibitors 7/7
Bucillamine role in penicillamine-enhanced PMN
effect on glutathione metabolism in locomotion 1745
mice 84/7 role in stimulus-induced cyclic AMP
Buformin hydrochloride elevation in neutrophils $105
effect on conformations of poly-L- role in W7 stimulation of Kt trans-
lysine 2397 port in human epithelia 1039
P-Bungarotoxin sequestration in liver, effect of
effect on cross-linking of presyn- ryanodine 1799
aptic plasma membrane proteins synaptosomal uptake
2043 effect of ethanol 39
Bunitrolol 4-hydroxylase effect of manganese 1537
in liver of Dark Agouti and Wistar in vas deferens smooth muscle cells,
rats 2241 effect of histamine 1545
Bupivacaine Calcium channel blockers
action at calcium channels 213 cancer chemotherapy 1514
Butacaine effect on catecholamine secretion
action at calcium channels 213 by chromaffin cells 190
Buthionine sulphoximine free radical scavenging and
effect on melphalan resistance inhibition of lipid peroxidation
in vitro and in vivo 439 735
effect on e-naphthylisothiocyanate- effect on palytoxin-induced catechol-
induced liver injury 1181 amine secretion 17